Brought to you by 
Corvas will merge with Dendreon
13 Mar 2003
Executive Summary
Corvas International (cancer and cardiovascular) has agreed to merge with Dendreon (cancer) in a tax-free reorganization valued at about $74.6mm.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com